PF-05230907治疗脑出血的1b期安全性研究
本研究为1期多中心开放标签临床试验,采用贝叶斯改良持续再评估法,评估单剂PF-05230907在急性脑出血患者中的最大耐受剂量及安全性。
要点
- 急性脑出血患者单剂PF-05230907在5–30 μg/kg范围内总体耐受。
- 30 μg/kg组出现深静脉血栓和脑缺血各1例。
- 研究终止时估计最大耐受剂量为24 μg/kg。
核心结论
- 单剂PF-05230907在脑出血患者中跨剂量范围似乎可耐受,血栓事件仅见于最高测试剂量组。
研究设计与样本
- 1期、多中心、开放标签临床试验,采用基于治疗中出现血栓栓塞或缺血事件的贝叶斯改良持续再评估法设计。
主要发现
- 30 μg/kg剂量组发生2例治疗中出现血栓栓塞或缺血事件(深静脉血栓和脑缺血)。
- 5至30 μg/kg剂量范围内未见其他明确的药物相关毒性。
关键数值与推荐
- 研究终止时估计最大耐受剂量为24 μg/kg,平均拟合剂量毒性估计为11.9%(95% CI,1.2%–27.4%)。
临床怎么用
- 在推荐治疗时间窗内招募受试者仍存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This study aimed to determine the maximum tolerated dose and to evaluate the overall safety and tolerability of single doses of PF-05230907 in subjects with acute intracerebral hemorrhage. METHODS: Individuals presenting with intracerebral hemorrhage were enrolled in a phase 1, multicenter, open-label clinical trial. A Bayesian modified continual reassessment method design based on treatment-emergent thromboembolic or ischemic events was adopted. Sequential dosing, an external data monitoring committee, and prespecified stopping rules were incorporated as safeguards. RESULTS: Twenty-one subjects received PF-05230907. The mean (±SD) age in years and intracerebral hemorrhage volume in mL at baseline were 62 (±9) and 18 (±11), respectively. Two treatment-emergent thromboembolic or ischemic events occurred (deep vein thrombosis and cerebral ischemia), in the 30 μg/kg dose group. There were no other clear drug-related toxicities at dose levels ranging from 5 to 30 μg/kg. At the time of study termination, the maximum tolerated dose was estimated to be 24 μg/kg, with a mean fitted dose-toxicity estimate of 11.9% (95% CI, 1.2%-27.4%). CONCLUSIONS: Single doses of PF-05230907 appeared to be tolerated across a range of doses in the intracerebral hemorrhage population, with thrombotic events observed only at the highest dose level tested. Recruitment within the recommended therapeutic window of opportunity remains a challenge. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02687191.
引用
- Silva Blas Y, Diringer MN, Lo B, et al. Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage. Stroke. 2020. PMID: 33272131. doi:10.1161/STROKEAHA.120.029789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。